{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:59:07Z","timestamp":1790668747703,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019383","name":"Cipla","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.vascn.2024.107526","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T20:54:29Z","timestamp":1717793669000},"page":"107526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Optimization of an  method for assessing pulmonary permeability of inhaled drugs using alveolar epithelial cells"],"prefix":"10.1016","volume":"128","author":[{"given":"Nitesh","family":"Shirsath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash","family":"More","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Sonawane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeevan","family":"Ghosalkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2024.107526_bb0005","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.3390\/pharmaceutics13091331","article-title":"Reparation of an inflamed air-liquid interface cultured A549 cells with nebulized nanocurcumin","volume":"13","author":"Altube","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vascn.2024.107526_bb0010","series-title":"Biopharmaceutics Classification System-Based Biowaivers Guidance for Industry","year":"2021"},{"key":"10.1016\/j.vascn.2024.107526_bb0015","doi-asserted-by":"crossref","first-page":"105178","DOI":"10.1016\/j.tiv.2021.105178","article-title":"Inter-laboratory variability of A549 cells grown under submerged and air-liquid interface conditions","volume":"75","author":"Borsova","year":"2021","journal-title":"Toxicology in Vitro"},{"key":"10.1016\/j.vascn.2024.107526_bb0020","doi-asserted-by":"crossref","unstructured":"Bosquillon, C.; Madlova, M.; Patel, N. et. al. A comparison of drug transport in pulmonary absorption models: Isolated perfused rat lungs, respiratory epithelial cell lines and primary cell culture. Pharmaceutical Research 2017, 34, 2532\u20132540. DOI: https:\/\/doi.org\/10.1007\/s11095-017-2251-y.","DOI":"10.1007\/s11095-017-2251-y"},{"key":"10.1016\/j.vascn.2024.107526_bb0025","doi-asserted-by":"crossref","first-page":"6010","DOI":"10.3390\/ijms20236010","article-title":"Effects of cadmium on ZO-1 tight junction integrity of the blood brain barrier","volume":"29; 20(23)","author":"Branca","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.vascn.2024.107526_bb0030","first-page":"1","article-title":"Drug delivery to the lung: Permeability and physicochemical characteristics of drugs as the basis for a pulmonary biopharmaceutical classification system (pBCS)","volume":"3","author":"Eixarch","year":"2010","journal-title":"J Epithelial Biol Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.vascn.2024.107526_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(00)00452-X","article-title":"Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery","volume":"208","author":"Foster","year":"2000","journal-title":"International Journal of Pharmaceutics"},{"issue":"2","key":"10.1016\/j.vascn.2024.107526_bb0040","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1006\/excr.1998.4172","article-title":"Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism","volume":"243","author":"Foster","year":"1998","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.vascn.2024.107526_bb0045","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/mp200415g","article-title":"Critical characteristics for corticosteroid solution metered dose inhaler bioequivalence","volume":"9","author":"Grainger","year":"2012","journal-title":"Molecular Pharmaceutics"},{"key":"10.1016\/j.vascn.2024.107526_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41120-015-0002-x","article-title":"Scope and relevance of a pulmonary biopharmaceutical classification system AAPS\/FDA\/USP workshop, 2015, Baltimore","volume":"2","author":"Hastedt","year":"2016","journal-title":"MD. AAPS Open."},{"key":"10.1016\/j.vascn.2024.107526_bb0055","doi-asserted-by":"crossref","first-page":"100002","DOI":"10.1016\/j.ooc.2020.100002","article-title":"Drug delivery for traditional and emerging airway models","volume":"1","author":"Karra","year":"2019","journal-title":"Organs-on-a-Chip"},{"issue":"8","key":"10.1016\/j.vascn.2024.107526_bb0060","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1023\/A:1016295406473","article-title":"Permeability of peptides and proteins in human cultured alveolar A549 cell monolayer","volume":"12","author":"Kobayashi","year":"1995","journal-title":"Pharmaceutical Research"},{"issue":"Suppl A","key":"10.1016\/j.vascn.2024.107526_bb0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0954-6111(98)90211-6","article-title":"Improved delivery of inhaled steroids to the large and small airways","volume":"92","author":"Leach","year":"1998","journal-title":"Respiratory Medicine"},{"key":"10.1016\/j.vascn.2024.107526_bb0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.17145\/jab.18.010","article-title":"Bioanalytical method development and validation: From the USFDA 2001 to the USFDA 2018","volume":"4","author":"Meesters","year":"2018","journal-title":"Guidance for Industry. J Appl Bioanal."},{"key":"10.1016\/j.vascn.2024.107526_bb0075","unstructured":"OECD, 2018. OECD guideline for testing of chemicals no 442E: In vitro skin sensitisation assays. (Paris, France), 2018."},{"key":"10.1016\/j.vascn.2024.107526_bb0080","unstructured":"OECD (2021), Test no. 439: In vitro skin irritation: Reconstructed human epidermis test method, OECD guidelines for the testing of chemicals, section 4, OECD publishing, Paris. DOI: Org\/10.1787\/9789264242845-en, 2021."},{"key":"10.1016\/j.vascn.2024.107526_bb0085","unstructured":"OECD (2023a), Test no. 491: Short time exposure in vitro test method for identifying (i) chemicals inducing serious eye damage and (ii) chemicals not requiring classification for eye irritation or serious eye damage, OECD guidelines for the testing of chemicals, section 4, OECD publishing, Paris, DOI: Org\/10.1787\/9789264242432-en, 2023."},{"key":"10.1016\/j.vascn.2024.107526_bb0090","unstructured":"OECD (2023b), Test no. 498: In vitro Phototoxicity - reconstructed human epidermis Phototoxicity test method, OECD guidelines for the testing of chemicals, section 4, OECD publishing, Paris, DOI: Org\/10.1787\/7b2f9ea0-en."},{"issue":"6","key":"10.1016\/j.vascn.2024.107526_bb0095","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4187\/respcare.06290","article-title":"Aerosol delivery devices for obstructive lung diseases","volume":"63","author":"Pleasants","year":"2018","journal-title":"Respiratory Care"},{"issue":"10","key":"10.1016\/j.vascn.2024.107526_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0165225","article-title":"An optimised human cell culture model for alveolar epithelial transport","volume":"11","author":"Ren","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vascn.2024.107526_bb0105","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/jps.24381","volume":"104","author":"Sakamoto","year":"2015","journal-title":"Journal of Pharmaceutical Sciences"},{"key":"10.1016\/j.vascn.2024.107526_bb0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.vascn.2017.02.023","article-title":"Evaluation of permeability alteration and epithelial-mesenchymal transition induced by transforming growth factor-\u03b21 in A549, NCI-H441, and Calu-3 cells: Development of an in vitro model of respiratory epithelial cells in idiopathic pulmonary fibrosis","volume":"86","author":"Togami","year":"2017","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"6","key":"10.1016\/j.vascn.2024.107526_bb0115","doi-asserted-by":"crossref","DOI":"10.1038\/sj.emboj.7600605","article-title":"E-cadherin is essential for in vivo epidermal barrier function by regulating tight junctions","volume":"23;24","author":"Tunggal","year":"2005","journal-title":"The EMBO Journal"},{"issue":"9","key":"10.1016\/j.vascn.2024.107526_bb0120","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1016\/j.mayocp.2021.03.016","article-title":"Why we should target small airways disease in our management of chronic obstructive pulmonary disease","volume":"96","author":"Usmani","year":"2021","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1016\/j.vascn.2024.107526_bb0125","doi-asserted-by":"crossref","first-page":"100966","DOI":"10.1016\/j.mtbio.2024.100966","article-title":"Pulmonary inhalation for disease treatment: Basic research and clinical translations","volume":"25","author":"Wang","year":"2024","journal-title":"Materials Today Bio"},{"key":"10.1016\/j.vascn.2024.107526_bb0130","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijpharm.2003.09.033","article-title":"Transport of proteins and peptides across human cultured alveolar A549 cell monolayer","volume":"28; 269(2)","author":"Wang","year":"2004","journal-title":"International Journal of Pharmaceutics"},{"issue":"2","key":"10.1016\/j.vascn.2024.107526_bb0135","doi-asserted-by":"crossref","first-page":"e6950","DOI":"10.1590\/1414-431x20176950","article-title":"Characterization of air-liquid interface culture of A549 alveolar epithelial cells","volume":"51","author":"Wu","year":"2018","journal-title":"BrazJ Med Biol Res."}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871924000364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871924000364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T22:09:41Z","timestamp":1737756581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871924000364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":27,"alternative-id":["S1056871924000364"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2024.107526","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of an in vitro method for assessing pulmonary permeability of inhaled drugs using alveolar epithelial cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2024.107526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107526"}}